共 50 条
- [1] Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in MiceBLOOD, 2012, 120 (21)Keilhack, HeikeYokoi, AkiraKnutson, Sarah K.Wigle, TimWarholic, NatalieKawano, SatoshiMinoshima, YukinoriHuang, Kuan-ChunKuznetsov, GalinaKumar, NamitaKlaus, Christine R.Allain, Christina J.Raimondi, AlejandraScott, Margaret PorterChesworth, RichardMoyer, Mikel P.Uenaka, ToshimitsuCopeland, Robert A.Richon, Victoria M.Pollock, Roy M.Kuntz, Kevin W.
- [2] A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutationsCANCER RESEARCH, 2012, 72Creasy, Caretha L.McCabe, Michael T.Korenchuk, SusanDiaz, ElsieOtt, HeidiThompson, Christine S.Ganji, GopiGorman, Shelby A.LaFrance, Louis V.Brandt, MartinMcHugh, CharlesVerma, Sharad K.Tummino, Peter J.
- [3] SAH derived potent and selective EZH2 inhibitorsBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1532 - 1537Kung, Pei-PeiHuang, BuwenZehnder, LukeTatlock, JohnBingham, PatrickKrivacic, CodyGajiwala, KetanDiehl, WadeYu, XiuMaegley, Karen A.
- [4] EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05): : 491 - 495Campbell, John E.Kuntz, Kevin W.Knutson, Sarah K.Warholic, Natalie M.Keilhack, HeikeWigle, Tim J.Raimondi, AlejandraKlaus, Christine R.Rioux, NathalieYokoi, AkiraKawano, SatoshiMinoshima, YukinoriChoi, Hyeong-WookScott, Margaret PorterWaters, Nigel J.Smith, Jesse J.Chesworth, RichardMoyer, Mikel P.Copeland, Robert A.
- [5] Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin LymphomaMOLECULAR CANCER THERAPEUTICS, 2014, 13 (04) : 842 - 854Knutson, Sarah K.Kawano, SatoshiMinoshima, YukinoriWarholic, Natalie M.Huang, Kuan-ChunXiao, YonghongKadowaki, TadashiUesugi, MaiKuznetsov, GalinaKumar, NamitaWigle, Tim J.Klaus, Christine R.Allain, Christina J.Raimondi, AlejandraWaters, Nigel J.Smith, Jesse J.Porter-Scott, MargaretChesworth, RichardMoyer, Mikel P.Copeland, Robert A.Richon, Victoria M.Uenaka, ToshimitsuPollock, Roy M.Kuntz, Kevin W.Yokoi, AkiraKeilhack, Heike
- [6] A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumorsEUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S55Italiano, A.Keilhack, H.Toulmonde, M.Coindre, J. M.Michot, J. M.Massard, C.Ottesen, L.Reyderman, L.Blakemore, S. J.Kraljevic, S.Thomson, B.McDonald, A.Ho, P. T.Ribrag, V.
- [7] Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitorCANCER SCIENCE, 2017, 108 (10): : 2069 - 2078Honma, DaisukeKanno, OsamuWatanabe, JunKinoshita, JunzoHirasawa, MakotoNosaka, EmiShiroishi, MachikoTakizawa, TakeshiYasumatsu, IsaoHoriuchi, TakaoNakao, AkiraSuzuki, KeisukeYamasaki, TomonoriNakajima, KatsuyoshiHayakawa, MihoYamazaki, TakanoriYadav, Ajay SinghAdachi, Nobuaki
- [8] Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated CancerTHERANOSTICS, 2019, 9 (17): : 5020 - 5034Ma, LinlinYan, YuqianBai, YangYang, YinhuiPan, YunqianGang, XiaokunKarnes, R. JeffreyZhang, JunLv, QiuboWu, QiangHuang, Haojie
- [9] Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical modelsCANCER RESEARCH, 2017, 77Drew, Allison E.Motwani, VinnyCampbell, John E.Tang, CuyueSmith, Jesse J.Chesworth, RichardCopeland, Robert A.Raimondi, AlejandraRibich, Scott
- [10] A potent EZH2 inhibitor exhibits long residence time and anti-tumor activityCANCER RESEARCH, 2015, 75Ott, Heidivan Aller, GlennWard, JessicaLe, BaoChauRominger, CynthiaFoley, JamesKorenchuk, SusanMcHugh, CharlesButticello, MichaelBlackledge, CharlesBrackley, JamesBurgess, JoelleDuquenne, CelineJohnson, NeilKasparec, JiriLaFrance, LouisLi, MeiMcNulty, KennethNewlander, KennethRomeril, StuartSchmidt, StanleySchulz, MarkSu, Dai-ShiSuarez, DominicTian, XinrongCarpenter, ChristopherLuengo, JuanKruger, RyanKnight, StevenMcCabe, Michael T.